New York City, NY: October 9, 2019- WorldGene Therapy MarketResearch Report is classified by key Gene Therapy manufacturers, regions, and various segmentation to offers all important details to the readers. A thorough analysis of Gene Therapy market based on product portfolio, applications, price, production processes included in Gene Therapy are calculated deeply. The market is hoped to have additional upcoming players which may lean to gigantic worldwide market development. Gene Therapy industry growth,scope, with Gene Therapy revenue are specifiy in this report.

Detailed study of Gene Therapy market competition, advancement, Gene Therapy development opportunities and factors restraining the market growth are study in detail. All the elementary market information like Gene Therapy consumer volume, market size, demand/supply analysis, and Gene Therapy gross margin study are included in this report. The changing competitive environment will lead to accretion of revenue in Gene Therapy market.

Worldwide Gene Therapy study will offers as a worthwhile guide for studying business opportunities and building the strategic business judgment which will gives benefit in Gene Therapy. The latest Gene Therapy trend and updated marketing strategies will foreseen the Gene Therapy market presentation in upcoming years.

Download Sample Copy of Gene Therapy Market Report Study 2019-2028 At:https://marketresearch.biz/report/gene-therapy-market/request-sample

This information relevant to innovations proceed,technical advancement, in Gene Therapy, press release, Gene Therapy marketing strategies are expanded in this report. The report also manage Gene Therapy market inspection on a global and regional basis to provide worldwide market projection and market share for the upcoming period 2019 to 2028.

Purview of the Gene Therapy Market Report:

The foreseen Gene Therapy market trends, industry development, sales margin estimated over the forecast period are included in this report. The process containing in Gene Therapy manufacturing, end users, sellers, buyers, manufacturers are analysed deeply in this report.

Key developments, supply chain static of Gene Therapy, innovations will guide the market players to build up the strategies for business. Obtaining crucial Gene Therapy information and structured it in a separate way will help enhnaced the decisions.

Global Gene Therapy Market Classification:

This report illustrate the competitive landscape sight of all the key players depend on their company profile, Gene Therapy sales profit, development stature, Gene Therapy import/export scheme and consumption rate. The Gene Therapy improvement and market revenue are provided for each and every region, manufacturer and Gene Therapy application of product. The leading manufacturers of global Gene Therapy market contains Amgen Inc, Oxford BioMedica PLC, Genethon, Applied Genetic Technologies Corporation, GlaxoSmithKline PLC, NewLink Genetics Corp., Spark Therapeutics Inc, Transgene SA, Kite Pharma Inc, Bluebird bio Inc and Novartis.

The Gene Therapy manufacturing regions like Asia-Pacific, Canada, United States, Italy, South America, Africa, Japan, Mexico, Brazil, Southeast Asia, UK, Australia, Germany, Russia, Europe, Middle East & Africa, France, India,North America, Korea, and China are included in this Gene Therapy report. Gene Therapy industry scope and statistical data related to past, current and future Gene Therapy market are analysed in this report study.

Eccentricity Of The Global Gene Therapy Market Report:

Study of latest and future Gene Therapy industry trends will give boost to growth opportunities. The upcoming information relevant to market share, revenue, and growth will beneficial while taking the business decisions. The separate study depend on regions, and various segments will provides all the minuscule details to the readers. Growth endorsement, study of company profiles of Gene Therapy major manufacturers and strategies endorse by major players will propel business vision. Usefulness of investment anaylsis, market existence, and upcoming Gene Therapy sections will determine the market scope in forecasting years.

Enquire about the report, talk with our specialist at:https://marketresearch.biz/report/gene-therapy-market/#inquiry

TOC of Gene Therapy Report:

Part 1 of the report offers data related to Gene Therapy product scope, industry outlook, growth opportunities, challenges to the Gene Therapy market growth and major propeling forces.

Part 2 provides overall detailing related to key Gene Therapy manufacturers, their sales revenue, and product cost structure forecast over 2019-2028.

Part 3 lists the competitive sight of the Gene Therapy market depend on the company profile, volume and market share forecast from 2019-2028.

Part 4 analysis the major regions giving contribution to the market growth, their sales margin, size and leading manufacturing countries includes with these regions.

Part 5,6 gives details related to Gene Therapy industry size and share of each manufacturers existing within the region, trends, Gene Therapy scope, and application, forecast from 2019-2028.

Part 7,8 serves global market study based on various segments, Gene Therapy sales volume, forecast from 2019-2028.

Part 9 provides the futuristic market data relevant to Gene Therapy like the projected development, revenue share, market scope, emerging regions and the growth prospects of the industry.

Part 10 covers the study of Gene Therapy marketing channels, vendors, traders and finally beneficial research conclusions are served.

This content has been distributed via WiredRelease press release distribution service. For press release service enquiry, please reach us atcontact@wiredrelease.com.

Excerpt from:
Gene Therapy Market Growth Prospects, Traders, Opportunities with Growth Factor By 2028 - Healthcare News

Recommendation and review posted by Bethany Smith

Zion Market Research published a new 110+ pages industry researchGene Therapy Market: by Type (Somatic Cell Gene Therapy and Germ Cell Gene Therapy) and by Application (Genetic Disorders, Cancer, Cardiovascular Disease, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 20172024.

TheGlobal Gene Therapy Market Is Expected To Reach Around USD 2,269 Million By 2024complete outline is crystal clear penned down in the GlobalGene Therapy Marketresearch report such that not only an unskilled individual but also a professional can easily extrapolate the entire Gene Therapy Market within a few seconds.The research study covers research data which makes the document a handy resource for managers, analysts, industry experts, and other key people get ready-to-access and self-analyzed study along with TOC, graphs and tables to help understand the market size, share, trends, growth drivers and market opportunities and challenges.

Download FREE PDF Sample Brochure for more Industry Insights @CLICK HERE NOW

The Gene Therapy Market research report covers major industry player profiles that include:

UniQure N.V, Spark Therapeutics LLC, Bluebird Bio, Juno Therapeutics, GlaxoSmithKline, Celgene Corporation, Shire Plc, Sangamo Biosciences, Dimension Therapeutics

This report employs the SWOT analysis technique for the assessment of the development of the most remarkable market players. It additionally considers the latest upgrades while assessing the development of leading market players. Moreover, in the global Gene Therapy Market report, the key product categories of the global Gene Therapy Market are included. The report similarly demonstrates supportive data related to the dominant players in the market, for instance, product offerings, revenue, segmentation, and business synopsis. The global Gene Therapy Market is as well analyzed on the basis of numerous regions.

Download FREE PDF Sample for more Insights@CLICK HERE NOW

Global Gene Therapy Market: Regional Analysis

To understand the competitive landscape in the market, an analysis of Porters five forces model for the market has also been included. The study encompasses a market attractiveness analysis, wherein all segments are benchmarked based on their market size, growth rate, and general attractiveness. This report is prepared using data sourced from in-house databases, secondary and primary research team of industry experts.

Browse Press Release@CLICK HERE NOW

The report answers important questions that companies may have when operating in the Global Gene Therapy Market. Some of the questions are given below:

What is the current CAGR of the Global Gene Therapy Market?

Which product is expected to show the highest market growth?

Which application is projected to gain a lions share of the Global Gene Therapy Market?

Which region is foretold to create the most number of opportunities in the Global Gene Therapy Market?

Will there be any changes in market competition during the forecast period?

Which are the top players currently operating in the global market?

How will the market situation change in the coming years?

What are the common business tactics adopted by players?

What is the growth outlook of the Global Gene Therapy Market?

Also, Research Report Examines:

Thanks for reading this article; you can also get individual chapter wise section or region wise report versions like North America, Europe or Asia.

Sorry! The Author has not filled his profile.

Read the original post:
Gene Therapy Market to exceed USD 2269 Million By 2024 - The Industry Today News

Recommendation and review posted by Bethany Smith

Cancer Gene Therapy Market SWOT Analysis And Forecast 2024

The Cancer Gene Therapy Market report has been added to Qurate Business Intelligence offering. The global Cancer Gene Therapy Market report offers the important data to help the firms cope up with the knowledge gap due to the advancements in the industry and effectively utilize the opportunities that present itself into the ever-changing market.

Cancer Gene Therapy Market highlights the information about the dominant players industries and market, technologies, and abilities over the trends and the developments of the industries. After deep research and analysis by the experts, they also disclosed the data about the strong contenders contributing in the market growth and expansion and challenging one another in terms of demand, supply, production, value estimation, revenue, and sales.

The latest report offers wide-ranging coverage of several important industry verticals along with key market players. It as well offers consistency on the part of analysis or estimation across a range of coverage areas and geographies.

Request Sample of Cancer Gene Therapy Market Report: https://www.qurateresearch.com/report/sample/HnM/2019-2024-global-and-regional-cancer-gene-therapy-industry/QBI-HNY-HnM-487185/

Major Key players of Cancer Gene Therapy Market:

Adaptimmune, GlaxoSmithKline, Bluebird bio, Merck, Celgene, Shanghai Sunway Biotech, BioCancell, Shenzhen SiBiono GeneTech, SynerGene Therapeutics, OncoGenex Pharmaceuticals, Genelux Corporation, Cell Genesys, Advantagene, GenVec, BioCancell, Celgene, Epeius Biotechnologies, Introgen Therapeutics, Ziopharm Oncology, Shenzhen SiBiono GeneTech, Altor Bioscience,

Type

Gene Induced Immunotherapy, Oncolytic Virotherapy, Gene Transfer

Application

Hospitals, Diagnostics Centers, Research Institutes

Cancer Gene Therapy MarketPromising Regions & Countries Mentioned In The Cancer Gene Therapy Market Report: North America (U.S and Canada and the rest of North America)Europe (Germany, France, Italy and Rest of Europe)Asia-Pacific (China, Japan, India, South Korea and Rest of Asia-Pacific)LAMEA (Brazil, Turkey, Saudi Arabia, South Africa and Rest of LAMEA)

Click here to get [emailprotected] https://www.qurateresearch.com/report/discount/HnM/2019-2024-global-and-regional-cancer-gene-therapy-industry/QBI-HNY-HnM-487185/

AbstractThe report covers the forecast and analysis for the Cancer Gene Therapy Market on a global and regional level.The report includes the positive and the negative factors that are influencing the growth of the market.The revenue generated by the prominent industry players has been analyzed in the report.The market numbers have been calculated using top-down and the bottom-up approaches.The Cancer Gene Therapy Market has been analyzed using S.T.E.E.P.L.E. Analysis (Social, Technological, Environmental, Economical, Political, Legal, Ethical) .The market is segmented on the basis of Cancer Gene Therapy Market type, software type, service type, solution type, and application type, which in turn is bifurcated on a regional level as well.All the segments have been evaluated based on the present and the future trends.The report deals with in-depth quantitative and qualitative analyses of the Cancer Gene Therapy Market.The report includes the detailed company profiles of the prominent market players.

Inquire more or share questions if any before the purchase on this report @ https://www.qurateresearch.com/report/enquiry/HnM/2019-2024-global-and-regional-cancer-gene-therapy-industry/QBI-HNY-HnM-487185/

The global Cancer Gene Therapy Market report conveys the information regarding the prcised escalation or decline in market growth due to several key factors. The analysts, using various analytical methodologies such as SWOT analysis, S.T.E.E.P.L.E. Analysis, etc. among others to generate the precise forecast belonging to the growth rate and upcoming opportunities in the market growth at the global level. The global Cancer Gene Therapy Market report represents the complete information of the market in an eye-catching and easily understandable way with examples, figures, graphs, and flowcharts.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Continued here:
Cancer Gene Therapy Market 2019 In-Depth Analysis of Industry Share, Size, Growth Outlook up to 2024 - Space Market Research

Recommendation and review posted by Bethany Smith

DUBLIN, Oct. 10, 2019 /PRNewswire/ -- The "Global DNA Read, Write and Edit Market" report has been added to ResearchAndMarkets.com's offering.

The scope of the report includes DNA read, write and edit technologies, applications, industries, initiatives, patents, and companies. The markets for read, write and edit products and services are given for 2017, 2018, 2019 (estimated) and 2024 (forecast).

This report reviews the main read, write and edit technologies and explains why genetic variation is important in clinical testing and disease. It then discusses significant large-scale research initiatives that impact read, write and edit applications. Of particular interest is a discussion of population-scale sequencing projects throughout the world, and their likely impact. The main market driving forces for read, write and edit products and services are listed and discussed.

The report quantifies each of the main market segments. The read (sequencing) market is quantified by delivered format, including sequencing workflow products (sample preparation kits and reagents, sequencing instruments and consumables, and informatics) and sequencing services (clinical diagnostics and sequencing services to applied market customers).

The sequencing workflow products market is quantified by type, that is, DNA isolation and extraction; target enrichment; library preparation; and informatics/ecosystems. The sequencing instruments and consumables market is given by platform (Sanger, NGS, and 3GS).

The sequencing services market is analyzed by end-user application (applied, clinical, and R&D). Within sequencing services, the applied market is analyzed by end-user application (agriculture, biopharma, consumer, microbiology, population-scale genomics, synthetic biology and other).

Also within sequencing services, the clinical market is analyzed and quantified by disease category (cardiovascular, clinical microbiology and infectious diseases, Mendelian disorders, metabolic/immune disorders, neurology, oncology, reproductive health, and transplant medicine).

The DNA write (synthesis) market is quantified by product type (oligonucleotides, synthetic biology parts, genes, and RNA therapeutics). The oligonucleotide market is analyzed by application (gene editing, sequencing, PCR, FISH, microarray, gene synthesis and other). The gene market is quantified by gene type (standardized, value-added). Finally, the RNA therapeutics market is quantified by platform (RNA interference, antisense oligos, micro RNA modulation, and mRNA) and by disease category (cancer, hematology, musculoskeletal, neurology, and rare diseases).

The DNA edit (gene editing) market is quantified by application (agriculture, biopharma, diagnostics, and therapeutics); editing platform (CRISPR, meganuclease, TALEN, ZFN). The gene-editing agriculture market is analyzed by product type (crop/seeds, livestock). The gene-editing biotechnology market is analyzed by product type (kits and reagents, cell line engineering, animal models and services). The gene-editing therapeutics market is analyzed by disease category (eye and rare diseases).

Specific geographic markets discussed include North America, Europe, Asia-Pacific, and the rest of the world (ROW).

Industry sectors analyzed include next-generation sequencing; long-read sequencing; DNA synthesis; RNA therapies; and gene editing.

More than 320 companies in the read, write and edit industry are profiled in this report.

The author also provides a summary of more than 180 of the main industry acquisitions and strategic alliances that took place from January 2018 through June 2019, including key alliance trends.

Market Summary

The DNA read, write and edit industry is at the beginning stages of its growth story; penetration of the key markets is still at an early stage. The data indicates that there is a significant future upside for sequencing across research, metagenomics, agriculture, synthetic biology, and clinical applications, among others.

The situation is similar for DNA writing and editing technologies, with clinical therapeutic applications, in particular, providing an enormous total available future market that is yet to be significantly penetrated. Major successes in this industry include the adoption of next-generation sequencing (NGS) for noninvasive prenatal testing; enabling the roles of synthetic DNA oligonucleotides and genes in the rise of the synthetic biology industry; and rapid adoption of CRISPR gene editing by research institutions and biopharma industries.

There is increasing interplay among the three DNA technology platforms, giving rise to innovative corporate strategies. For example, Arbor Biotechnologies employs sequencing, gene synthesis, and artificial intelligence to perform high-throughput discovery of biomolecules, including new CRISPR proteins.

Report Scope

Key Topics Covered

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Overview

Chapter 4 Technology Background

Chapter 5 DNA Read, Write and Edit Initiatives

Chapter 6 DNA Read, Write and Edit Applications

Chapter 7 DNA Read, Write and Edit Industries

Chapter 8 Acquisitions and Strategic Alliances

Chapter 9 DNA Read, Write and Edit Markets

Chapter 10 Patents

Chapter 11 Nucleic Acid Read, Write and Edit Company Profiles

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/7jlxd8

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Read the original here:
Analysis on the Global DNA Read, Write & Edit Market, 2017-2019 and Forecast to 2024 - PRNewswire

Recommendation and review posted by Bethany Smith

Zion Market Research published a research report containing 110+ pages titled Gene Therapy Market: by Type (Somatic Cell Gene Therapy and Germ Cell Gene Therapy) and by Application (Genetic Disorders, Cancer, Cardiovascular Disease, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 20172024 in its research offering. This report is well crafted with a combination of the crucial data associated with the worldwide market, along with key factors liable for the demand for its services and merchandise. The report highlights the newest technological developments and new launches that assist our customers to set up their future-based potential products, make wise business selections to meet the projected demand ratio.

This report is an excellent presentation of critical dynamics, regional growth, competition, and other important aspects of the global Gene Therapy Market. This report will provide accurate market figures and statistics that include market CAGR, revenue, volume, consumption, production, market shares, price, and gross margin. Each regional market analysis in the report is carefully analyzed to explore key opportunities and business prospects they are expected to offer in the near future. This report also includes major market players in the global Gene Therapy market on the basis of various factors including their past market performance, market size & share, by product analysis, distribution channels, marketing strategies, etc. This equips players with crucial information and data to improve their business tactics and ensure a strong foothold in the global Gene Therapy market.

To Know More, Request Sample Report @ http://www.zionmarketresearch.com/sample/gene-therapy-market

How this report helps you?

Major Company Profiles Included in This Report:

UniQure N.V, Spark Therapeutics LLC, Bluebird Bio, Juno Therapeutics, GlaxoSmithKline, Celgene Corporation, Shire Plc, Sangamo Biosciences, Dimension Therapeutics

Key Highlights of TOC

Industry Overview: This starts with a product overview and scope of the global Gene Therapy market. It also gives consumption and production growth rate comparisons by application and product respectively. It also includes a glimpse of the regional study and market size analysis for the review for the forecasted period.

Major Company Profiles: Each company profiled in the report is assessed for its market growth keeping in view vital factors such as price, gross margin, revenue, production, markets served, main business, product specifications, applications, and introduction, areas served, and production sites.

Market Dynamics: The readers are provided with a comprehensive analysis of market challenges, demand, market influence factors, growth drivers & restraints, global opportunities, and trends.

Market Forecast: The research report will provide forecast by application, price, revenue, and production forecast by product, consumption forecast by region, production forecast by region, and production and revenue forecast.

Report Methodology and Data Source Used: This report includes the publishers disclaimer, list of authors, major primary and secondary sources, and research approach.

Request for a Report PDF Brochure for Brief Analysis Summary @ http://www.zionmarketresearch.com/requestbrochure/gene-therapy-market

The Gene Therapy market report keenly emphasizes on industrial affairs and developments, approaching policy alterations and opportunities within the market. The regional development methods and its predictions are explained in every key point that specifies the general performance and issues in key regions such as the US, Asia Pacific, Middle East, and Europe. Various aspects such as production capability, demand, product value, material parameters and specifications, distribution chain and provision, profit and loss, are explained comprehensively in the Gene Therapy market report.

The report hands in-depth segmentation of the worldwide market based on supported technology, product type, application, and numerous processes and systems. The report attains economical competitive analysis, business trends within the market, and alternative key characteristics of the worldwide Gene Therapy market. Our experts have genuinely concatenated the Gene Therapy market report by alluding the lists and figures, primary sources, with an intention to boost the understanding of the associated procedural terms and conditions.

Some of the major regions covered in this Gene Therapy Market report:

Read More Report Details @ http://www.zionmarketresearch.com/report/gene-therapy-market

The Gene Therapy market report includes the leading advancements and technological up-gradation that engages the user to inhabit with fine business selections, define their future-based priority growth plans, and to implement the necessary actions. The global Gene Therapy market report also offers a detailed summary of key players and their manufacturing procedure with statistical data and a profound analysis of the products, contribution, and revenue.

Every information given in the report is sourced and verified by our expert team and is collated with precision. To give a broad overview of the current global market trends and strategies led by key businesses, we present the information in a graphical format such as graphs, pie-charts with a superior illustration.

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the clients needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to usafter allif you do well, a little of the light shines on us.

Contact Us:

Zion Market Research

244 Fifth Avenue, Suite N202New York, 10001, United States

Tel: +49-322 210 92714

USA/Canada Toll-Free No.1-855-465-4651

Email: [emailprotected]

Website: http://www.zionmarketresearch.com

Sorry! The Author has not filled his profile.

Continue reading here:
Global Gene Therapy Market Revenue Will Grow Over USD 2269 Million By 2024 - Industry PressRelease

Recommendation and review posted by Bethany Smith

Heres our recent analysis on Global Gene Therapy for Age-related Macular Degeneration Market research report 2019-2025 which primarily explains the crucial growth factors of the market that are impacting the Gene Therapy for Age-related Macular Degeneration industry along with the upcoming possibilities that are expected to influence the Gene Therapy for Age-related Macular Degeneration market during the forecast session between 2019 to 2025. In this study, the global Gene Therapy for Age-related Macular Degeneration market is evaluated through distinct industry elements such as restraints, opportunities, and drivers to help the users to have a better understanding about the fundamental overview of the Gene Therapy for Age-related Macular Degeneration market.

Request for sample copy of the report: https://spiremarketresearch.com/report/global-gene-therapy-agerelated-macular-degeneration-market-2472#request-sample

In 2019, the global Gene Therapy for Age-related Macular Degeneration market size is valued at million US$ and it will be anticipated to gain million US$ by the end of the year 2025, which is boosting at a CAGR during the predicted period. While, in the Chinese continent, the Gene Therapy for Age-related Macular Degeneration market size is estimated at xx million US$ and it will grow about xx million US$ in 2025, with a CAGR of xx % from 2019-2025. The research report evaluates 2018 as the base year and 2019-2025 has been determined as the forecast timespan to estimate the Gene Therapy for Age-related Macular Degeneration market size.

Leading Players of the Gene Therapy for Age-related Macular Degeneration market are:

RetroSense TherapeuticsREGENXBIOAGTC

Gene Therapy for Age-related Macular Degeneration Market segmented by product types:

SubretinalIntravitrealUnspecified

Applications can be divided as:

MonotherapyCombination Therapy

Inquiry before buying the Gene Therapy for Age-related Macular Degeneration market report: https://spiremarketresearch.com/report/global-gene-therapy-agerelated-macular-degeneration-market-2472#inquiry-for-buying

The research study accumulates the global Gene Therapy for Age-related Macular Degeneration market size on the basis of major topographical regions like Unites States, China and other zones including Japan, India, Korea, and Southeast Asia. Furthermore, the report firmly explains plenty of key factors including revenue share, Gene Therapy for Age-related Macular Degeneration market size, sales volume, and growth rate of each company. It also describes the statistical information regarding the revenue, Gene Therapy for Age-related Macular Degeneration market share and sales by regions, types, and applications. Meanwhile, it represents historical data from 2014 to 2019 and forecast to 2025.

This report analyzes essential details like price, production volume, market share, growth rate, and Gene Therapy for Age-related Macular Degeneration market value for the key players and collects informative data from 2014 to 2019 for the leading companies in USA, China, and European Union. Therefore, this study offers a brief introduction of the worldwide Gene Therapy for Age-related Macular Degeneration market along with in-depth evaluations for the revenue from 2019 to 2026 and determines market dimensions with respect to the provided aspects. The current industry vendors, stakeholders, and consultants are also included in the Gene Therapy for Age-related Macular Degeneration market in order to articulate the several paths and also implements gathered choices.

Excerpt from:
Gene Therapy for Age-related Macular Degeneration Market Growth Analysis Reports by Companies RetroSense Therapeutics, REGENXBIO - The Chicago...

Recommendation and review posted by Bethany Smith

Zion Market Researchpublished a new industry research reportGlobal Gene Therapy Market Is Expected To Reach Around USD 2,269 Million By 2024is all around created with a blend of the significant information related with overall Gene Therapy Market, alongside key components obligated for the interest for its administrations and product.(Sample Copy Here)Gene Therapy Marketreport also provide a thorough understanding of the cutting-edge competitive analysis of the emerging market trends along with the drivers, restraints, challenges, and opportunities in the Market to offer worthwhile insights and current scenario for making right decision. The report covers the prominent players in the market with detailed SWOT analysis, financial overview, and key developments of the products/services from the past three years. Moreover, the report also offers a 360 outlook of the market through the competitive landscape of the global industry player and helps the companies to garnerGene Therapy Marketrevenue by understanding the strategic growth approaches.

Request For Free Sample ofGene Therapy MarketReport:www.zionmarketresearch.com/sample/gene-therapy-market

Table of Contents

Get Free Brochure ofGene Therapy MarketReport:www.zionmarketresearch.com/requestbrochure/gene-therapy-market

The Gene Therapy Market report includes the leading advancements and technological up-gradation that engages the user to inhabit with fine business selections, define their future-based priority growth plans, and to implement the necessary actions. The global Gene Therapy Market report also offers a detailed summary of key players and their manufacturing procedure with statistical data and profound analysis of the products, contribution, and revenue.

This report focuses on price, sales, revenue and growth rate of each type, as well as the types and each type price of key manufacturers, through interviewing key manufacturers. Second on basis of segments by manufacturers, this report focuses on the sales, price of each type, average price ofGene Therapy Market, revenue and market share, for key manufacturers.

Browse Press Release@www.zionmarketresearch.com/news/gene-therapy-market

This report focuses on Time and Expense Management System volume and value at global level, regional level and company level. From a global perspective, this report represents overall Time and Expense Management System market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan. At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

Available Array of Customizations:

The classification of the global Gene Therapy Market is done based on the product type, segments, and end-users. The report provides an analysis of each segment together with the prediction of their development in the upcoming period. Additionally, the latest research report studies various segments of the global Gene Therapy Market in the anticipated period.

Also, Research Report Examines:

Lastly, with a team of vivacious industry professionals, we offer our clients with high-value market research that, in turn, would aid them to decipher new market avenues together with new strategies to take hold of the market share.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia

Browse for more Research Reports:fnfresearch.com

Sorry! The Author has not filled his profile.

View original post here:
Global Gene Therapy Market to Accumulate Revenues Worth US $2269 Million By 2024 - Market News Network

Recommendation and review posted by Bethany Smith

Introduction

Mereo BioPharma (MREO) is a British small-cap ($62M) biopharma developing therapeutics for rare disorders as well as endocrine and oncological diseases. MREO has a diverse pipeline including MPH-966 (alvelestat), BCT-197 (acumapimod), and OMP-305B83 (navicixizumab) for alpha-1 antitrypsin deficiency, chronic obstructive pulmonary disease, and ovarian cancer, respectively. The focus of this article is BGS-649 (leflutrozole), a drug asset licensed from Novartis (NVS) that is in clinical development for treating hypogonadotropic hypogonadism (Hypo-H).

Hypogonadism is a medical condition characterized by a deficiency in testosterone, the primary male circulating sex hormone synthesized in the gonads. Hypogonadism can present itself during fetal development, before puberty or during adulthood. Testosterone is important in the development and maturation of reproductive tissues. Symptomatic events of this disorder are decreased libido, impaired erectile function, muscle weakness, increased adiposity, depressed mood, and decreased vitality.

Hypogonadism can be triggered by a primary testicular disorder (hypergonadotropic; Hyper-H) whereas hypogonadotropic hypogonadism (Hypo-H) is a consequence of congenital or acquired diseases that affect the hypothalamus and/or the pituitary gland.

The hypothalamus (i.e. brain), pituitary (i.e. endocrine), and gonadal (i.e. reproductive) glands are all often known as hypothalamic-pituitary-gonadal axis because they all act in concert in the development and regulation of the reproductive and immune systems. Any alteration in this axis induces changes in the hormones produced by each gland that can affect their various local and systemic effects on the body. Hypo-H is frequently reported in metabolic disorders such as obesity, type 2 diabetes, and metabolic syndrome.

Men who present with Hyper-H do not respond to hormone replacement medication because the disorder is caused by primary testicular failure. Testosterone hormone replacement is the mainstay treatment for Hypo-H to normalize testosterone levels and restore fertility. Alternative options include gonadotropin therapy regimen to induce endogenous testosterone, aromatase inhibitors, and selective estrogen receptor modulators.

BGS-649 (leflutrozole) is a novel once-weekly oral aromatase inhibitor in clinical development as first-line therapy for the treatment of Hypo-H in obese men. The thesis is that BGS-649 normalizes testosterone levels by inhibiting aromatase and is, therefore, expected to improve the related conditions. The premise is that lower levels of testosterone in obese men with Hypo-H is driven by high levels of the aromatase enzyme in fat tissue which irreversibly converts testosterone into estradiol. Aromatase inhibitors are widely used therapeutically in breast cancer.

Clinical Data: A Phase 2b clinical trial of BGS-649 in 271 patients with Hypo-H achieved its primary clinical endpoint of total testosterone normalization:

in over 75% of subjects after 24 weeks of treatment, and in at least 90% of patients after 24 weeks at the two highest doses. All three doses met all secondary endpoints, including the improvement of testosterone luteinizing hormone (LH.) and follicle stimulating hormone (FSH.) levels. The exploratory endpoint of improvement in total motile sperm count was also met.

A safety extension study completed in 143 patients successfully demonstrated that none of the doses of BGS-649 met the lower bound (95% confidence interval) of the pre-specified safety criterion of a greater than 3% reduction in lumbar spine bone mineral density (BMD) after 48 weeks of treatment. The extension study also demonstrated normalization of testosterone in more than 90% of the patients at all three doses and maintenance of the effects on LH and FSH.

Individuals with Hypo-H lack or have low levels of gonadotropin-releasing hormone (GnRH.). GnRH is a peptide hormone secreted from the hypothalamus and stimulates gonadotropic cells in the anterior pituitary gland to release LH and FSH for normal gonad function including testosterone production by the testes. The observation that BGS-649 therapy was associated with normal FSH and LH levels in the Phase 2b study could suggest these patients also had GnRH levels normalized or elevated.

The prevalence of Hypo-H was estimated to be 1:10,000 to 1:86,000 individuals 20 years ago - meaning the prevalence could be higher due to increasing rates of obesity.

Upcoming catalytic events are:

Setrusumab for Osteogenesis Imperfecta (OI.)

12-month data from Phase 2b ASTEROID study in adult OI patients expected in Q4 2019. In May 2019, Mereo reported positive 6-month interim data from the fully-enrolled ASTEROID study. These data were accepted for a late-breaking oral presentation at the upcoming American Society for Bone and Mineral Research (ASBMR) 2019 Annual Meeting to be held from September 20-23 in Orlando, FL, USA. The Company expects to report 12-month topline data from the blinded portion of the study in Q4 2019. There are currently no FDA or EMA-approved treatments for OI.

Pivotal pediatric study ready in the EU and Canada. In addition to evaluating setrusumab in adult OI patients, Mereo's Paediatric Investigation Plan (PIP) has been approved by the EMA and a study design has been agreed for a pivotal registration trial in children. Mereo is also exploring an extension of the planned pivotal study into the U.S.

Alvelestat for Severe Alpha-1 Antitrypsin Deficiency (AATD.)

Enrollment continuing for the Phase 2 proof-of-concept study in severe AATD patients with topline data expected in mid-2020. If the results are positive, Mereo intends to commence a pivotal trial in the EU and the U.S. in AATD as soon as possible thereafter.

Investigator-sponsored clinical studies underway in AATD and also in bronchiolitis obliterans syndrome (BOS) as a result of graft-versus-host disease (GvHD) in patients undergoing hematopoietic stem cell transplantation (HSCT). BOS is an orphan disease characterized by inflammatory obstruction of the lung's tiniest airways and is the primary cause of death in patients who receive lung transplants. Based on the preliminary clinical data to-date, Mereo intends to investigate the use of alvelestat to treat patients with BOS following a lung transplant.

Partnering Discussions Continue for Broad Portfolio of Clinical-Stage Programs

Leflutrozole for Hypogonadotropic Hypogonadism .. Following the positive Phase 2b and six-month extension data reported in 2018, earlier this year Mereo held an advisory board to consider the future development strategy for leflutrozole, with a focus on the positive effects on semen parameters. Mereo has decided that future product development will focus on male fertility.

Acumapimod for Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) is Phase 3-ready following a successful Type B End of Phase 2 meeting with the FDA and agreed outline for a pivotal Phase 3 clinical trial program. Recently, a positive Scientific Advice Working Party (SAWP.) also took place with the EMA.

Navicixizumab for Advanced Platinum-Resistant Ovarian Cancer. In July 2019, Mereo held a successful Type B End of Phase 1 meeting with the FDA regarding a potential pathway for accelerated approval for navicixizumab for the treatment of patients with advanced ovarian cancer. Mereo and the FDA discussed, and agreed in principle, an outline for the design of a Phase 2 clinical trial that could potentially support the accelerated approval of navicixizumab in patients with ovarian cancer (including peritoneal or fallopian tube cancer) who have become resistant to prior therapies.

Etigilimab for Advanced Solid Tumors. Etigilimab has completed a Phase 1a/b trial of etigilimab, administered as either a single-agent or in combination with nivolumab, in patients with advanced or metastatic solid tumors.

The biggest risk is the low cash reserve. As highlighted above, MREO is seeking partnership agreements for some of its clinical programs. Partnership agreements would provide the financial stability needed to advance its clinical pipeline.

At the end of Q2/2019, it reported cash, cash equivalents, and short-term investments of $45.06M (after conversion from pounds sterling). Institutional ownership currently stands at 1.88%, with 43 institutional holders accounting for 1,805,180 total shares. Analysts recommend a buy with an average price target of $7.20.

CEO Dr. Denise Scots-Knight on the future:

Our team remains focused on advancing discussions with potential partners to help us further realize the value of these assets and we look forward to updating you regarding these discussions in the future. In addition to the progress have highlighted regarding our development programs, we also continue the build out of our senior Management Team and board of directors to ensure that we have the necessary expertise and are well positioned as our programs continue to advance.

Thanks for reading. While I occasionally cover companies like this, my focus remains investment opportunities in liver therapeutics, specifically NASH and Cholestatic liver diseases, which are exclusive to members of my private investing community, Liver Therapy Forum Marketplace.

As a Ph.D. trained liver biomedical scientist & Scientific Consultant, I provide:

Novel mechanistic insights and "updating thesis" highlighting promising drug candidates.

Exclusive access to full-length in-depth research analytical articles, KOL interviews, newsletters/digests, and Q & A chat board.

Actionable events to minimize risks and grow your investments.

Knowledge and wisdom required to understand the diverse and complex NASH therapeutics landscape.

Sign-up today to grow your investments!

Disclosure: I/we have no positions in any stocks mentioned, but may initiate a long position in MREO over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: As always, my articles are meant to facilitate your understanding. Readers are expected to form their own trading plan, do their own research and take responsibility for their own actions. Investing in common stock can result in partial or total loss of capital. Please implement due diligence and invest wisely.

Originally posted here:
Mereo BioPharma And Leflutrozole In Hypogonadotropic Hypogonadism - Seeking Alpha

Recommendation and review posted by Bethany Smith

Hypogonadism is defined as hormonal disorder in which the glands (gonads & ovaries) produce little or no hormones causing its deficiency in the body. Hypogonadism in males refers to deficiency of testosterone due to dysfunction of either of the testes. Female hypogonadism refers to deficiency of estrogen or progesterone due to reduced activity of the ovaries. Hypogonadism is classified into two types: primary hypogonadism (testicular failure) and central hypogonadism (hypothalamic-pituitary axis dysfunction). Other major causes of hypogonadism include autoimmune disorder, genetic disorder, severe infections, and liver and kidney diseases. Generally, hormone and imaging tests are used to diagnose hypogonadism.

According to the Boston University School of Medicine, around 4 million to 5 million men in the U.S. were affected with hypogonadism in 2003. The incidence of hypogonadism in men aged between 40 years and 69 years in the country is around 481,000 new cases per year. According to the European Male Aging Study, the prevalence of late onset hypogonadism in men aged between 40 and 79 was 2.1% in 2016. Studies suggest that hypogonadism in adult men is often underdiagnosed and undertreated and only 5%. According to the Urology Care Foundation, hypogonadism is a chronic condition which would require lifelong treatment. The treatment for hypogonadism depends on the cause and concern about fertility and includes treatment such as hormone replacement therapy or assisted reproduction.

Men with heart disease, HIV, COPD, or renal disease have high prevalence of hypogonadism. Factors such as rising prevalence of type 2 diabetes and obesity further increase the incidence of hypogonadism. Growth of the global hypogonadism treatment market is attributed to rise in geriatric population, increase in infertility, and improved diagnosis. However, growing concerns about the potential side effects, availability of generic drugs, and preference for other natural hormonal boosters and supplements are likely to hamper the growth of the hypogonadism treatment market. Increasing awareness, awaiting approvals for new generation drugs in pipeline, and technological advancements present significant opportunities in the hypogonadism treatment market.

The primary treatment option for hypogonadism is hormone replacement therapy. Based on product type, the market has been classified into testosterone replacement therapy, estrogen therapy, and progesterone therapy. Testosterone replacement therapy is the fastest growing segment as hypogonadism is more prevalent in men. The segment is expected to hold major share of the global market during the forecast period.

Browse more detail information about this report visit at at https://www.transparencymarketresearch.com/hypogonadism-treatment-market.html

In terms of mode of administration, the hypogonadism treatment market has been broadly classified into transdermal patch, topical gel, buccal tablets, implantable pellet, intramuscular injections, and oral tablets. Transdermal patch followed by topical gels are anticipated to be the fastest growing segments as these provide steady route of administration and are easily modifiable over a short period of time. The oral and buccal tablets segments are anticipated to experience sluggish growth during the forecast period due to high side effects and liver diseases.

Based on the distribution channel they are segmented into hospital pharmacies, retail pharmacies and others. The major market share for the hypogonadism treatment market is for the retail pharmacies segment and is anticipated to rule the market during the forecast period as continuous long term treatment is required for the hypogonadism patient.

In terms of region, the global hypogonadism treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is the largest market for hypogonadism treatment, accounting for more than half of the market share due to the factors such as increased adoption of newer highly advanced products, rising awareness about hormonal disorder including various treatment options available, and advancing health care infrastructure. However, Asia Pacific is anticipated to be the fastest growing market during the forecast period due to increasing urbanization and rise in the patient population.

Key players in the global hypogonadism treatment market are Bayer AG, Abbott Laboratories, Inc., Merck Serono, Sanofi, Merck & Co., Inc., Actavis, Inc., AbbVie Inc., AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Endo International plc, Ferring Holding S.A., and Laboratoires Genevrier.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Request For Custom Research At https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=30392&source=atm

The study is a source of reliable data on: Market segments and sub-segments Market trends and dynamics Supply and demand Market size Current trends/opportunities/challenges Competitive landscape Technological breakthroughs Value chain and stakeholder analysis

The regional analysis covers: North America (U.S. and Canada) Latin America (Mexico, Brazil, Peru, Chile, and others) Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg) Eastern Europe (Poland and Russia) Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand) Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industrys value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report: A complete backdrop analysis, which includes an assessment of the parent market Important changes in market dynamics Market segmentation up to the second or third level Historical, current, and projected size of the market from the standpoint of both value and volume Reporting and evaluation of recent industry developments Market shares and strategies of key players Emerging niche segments and regional markets An objective assessment of the trajectory of the market Recommendations to companies for strengthening their foothold in the market

Note:Although care has been taken to maintain the highest levels of accuracy in TMRs reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Request for TOC of This Report visit at https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=30392&source=atm

See original here:
Hypogonadism Treatment Market to Witness an Outstanding Growth by 2017 2025 - Space Market Research

Recommendation and review posted by Bethany Smith

Patent Expiry Blow Dealt to TRT Market Could be Softened by Growing Prevalence of Hypogonadism

A wide range of testosterone replacement therapy (TRT) products containing different active ingredients have been made available by a large number of both global and local manufacturers. With various studies estimating the number of men affected by hypogonadism (testosterone deficiency) at 30% worldwide, the demand for TRT is poised to increase gradually in the years ahead. The condition primarily affects men aged between 40 and 79 years, making this demographic a key target segment for market players.

Obtain Report Details @https://www.transparencymarketresearch.com/testosterone-replacement-therapy.html

However, the market is currently at a crucial juncture with top performing products losing their patents in the next few years. This will no doubt cause a major dent in revenues of key market players. However, some of this impact could be reduced by the heightened demand for and awareness levels about the benefits of advanced TRT products. Many of these products are now being utilized in testosterone deficiency treatment are likely to support market growth during the forecast period.

TRT Creams and Gels Continue to See Strong Sales Worldwide but Injections Racing Ahead

For the purpose of this study, the global testosterone replacement therapy market has been segmented on the basis of product type into creams/gels, patches, injections, gums/buccal adhesives, implants and oral drug forms. Of these, the creams/gels segment led the global market, as overall sales were mainly impelled by key branded formulations such as AndroGel from AbbVie, Inc. Axiron from Eli Lilly and Company, and Fortesta, Testim, and Natesto from Endo Pharmaceuticals Inc.

Get Sample with Latest Research @https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1097

Ease of use and comparatively less side effects have been the winning characteristics of gels/cream TRT products. However, this segment is expected to lose its current hold on the market owing to patent expirations of branded formulations.

TMR expects the injections product segment to witness the fastest CAGR from 2016 to 2024. This will be possible mainly because consumers are now more open to using these low priced products a factor aided by the increasing availability of self-administered forms of these products globally.

On the basis of active ingredients, the TRT market is segmented into testosterone, methyl testosterone, testosterone undecanoate, and testosterone enanthate and testosterone cypionate. Of these, testosterone as an active ingredient dominated the global TRT market in 2015. However, other active ingredients are expected to cover much ground through the forecast period. The demand for ester forms of testosterone such as testosterone cypionate and testosterone undecanoate is projected to show a healthy rise. Testosterone undecanoate is expected to witness the fastest growth through the reports forecasting horizon from 2016 to 2024.

Request Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1097

North America Leads TRT Market but Scales Tipping in Favor of Asia Pacific

Of the five broad geographical segments of the global testosterone replacement therapy market, North America accounted for the largest share (84.7%) of the market and was followed by Europe In 2015. The other key segments are Europe, Asia Pacific, Middle East and Africa (MEA), and Latin America.

The demand for advanced TRT products was especially strong in the U.S. in 2015 as the country accounted for 95% of the North America TRT market in that year, TMR has observed. Asia Pacific will greatly benefit from higher healthcare investments being channeled into the region and is expected to witness the fastest CAGR in the TRT market during the forecast period. China and India are markets that companies in the TRT market cannot ignore. In South Korea and Japan, on the other hand, the sizeable geriatric population and strong positive sentiments will aid the consumption of TRT products. Brazil is the key TRT market in Latin America with the single largest share 2015.

The key players operating in the global testosterone replacement therapy market are AbbVie, Inc., Allergan plc, Bayer AG, Endo Pharmaceuticals, Inc., Eli Lilly and Company, Kyowa Kirin International plc, Mylan N.V., Novartis AG, and Pfizer, Inc. The testosterone replacement therapy market is somewhat consolidated with presence of a few large global players and some local vendors that are operating in the international market.

View original post here:
Testosterone Replacement Therapy Market: Increase in Incidence of Testosterone Deficiency to Drive the Global Market - Online News Guru

Recommendation and review posted by Bethany Smith

A new study published at the Journal of Urology shows a significant improvement in sexual and urinary functions and in the quality of life of men with hypogonadism who undergo long-term testosterone replacement therapy.

Urinary Health

Testosterone is a steroid hormone involved in the regulation of sexual function, urinary tract health and metabolism, as well as other important functions. In most men, testosterone levels decrease slowly with age and cannot cause immediate serious symptoms. However, some people may experience many signs and symptoms, such as a clinical condition called testosterone deficiency (TD) or male hypogonadism, which is attributed to inadequate testosterone levels. As a result, they experience symptoms ranging from fatigue, erectile dysfunction, low energy, decreased mood, and increased risk of diabetes.

Scientists from the Boston University School of Medicine have worked with a group of urologists in Germany to investigate the effects of prolonged testosterone replacement therapy on urinary tract health, sexual function, and quality of life of men with diagnosed symptomatic testosterone deficits. The study included more than 650 men aged between 50 and 60, some with an unexplained testosterone deficiency and others with known genetic and autoimmune causes of hypogonadism.

Testosterone treatment in men would enlarge the prostate and aggravate symptoms of the lower urinary tract according to Dr. Abdulmaged Traish a professor of urology at BUSM.

However, he and Dr. Gheorghe Doros, professor of biostatistics at BUSPH, discovered that despite the increased size of the prostate in the testosterone therapy group, there were fewer urinary symptoms such as frequent urination, incomplete emptying of the bladder, weak urine flow and waking up at night.

In addition to these subjective improvements, scientists conducted objective tests that showed that men who were treated with testosterone emptied their bladders more completely. Finally, testosterone treatment also increased patient outcomes based on the evaluation of their sexual erection health and overall quality of life.

The results of this study are of great importance for men with symptomatic testosterone deficits. Traish emphasized the value of this treatment option and stated that testosterone therapy is well tolerated with progressive and continuous improvement of urinary and sexual function and overall quality of life.

Read this article:
Testosterone Therapy Can Improve Urinary and Sexual Function in Men with Low T - Gilmore Health News

Recommendation and review posted by Bethany Smith

Hate group leaderMichelle Cretella of American College of Pediatricians dispenses medical advice based on Church dogma, not medical science.

via YouTube

The problem is: the thousands of people who die while taking these drugs are likely the terminally ill cancer patients who receive hormone blockers to fight hormone-sensitive cancers, like prostate cancer, according to experts.

Enter hate group leader Michelle Cretella (American College of Pediatricians)

She also pointed out that the FDA report shows that there were 11 deaths of children linked to this drug, none of whom were being treated for prostate cancer.

Without her knowledge, someone injected this crank with some sodium pentothol:

The use of Lupron to block puberty in children with gender dysphoria is not FDA approved in short because puberty is not a disease, she said.

In fact, giving puberty blockers to physically healthy children induces the disease known as hypogonadotrophic hypogonadism.

None of this blather has anything whatsoever to do with the wellbeing of children. The intent is to defend the teachings of the Catholic Church. At the risk of being repetitive, belief systems are based on faith. Medical science is based on evidence. The Church is out of bounds for attempting to conform the science to religious dogma.

Not treating pediatric gender dysphoria poses a significant risk of self-harm. Not treating pediatric gender dysphoria because of Catholic dogma is irresponsible and stunningly stupid. Any parent who follows Cretella's advice or the ramblings of LifeSiteNews is guilty of child abuse. Cretella's former professional society, the American Academy of Pediatrics, recommends gender-affirming care. That is based on exhaustive study.

Who are you going to listen to? A religious crank who has not practiced medicine in years (presumably to avoid continuing education obligations) or the professional associations whose only concern is the wellbeing of children?

Related content:

Read the original here:
Michelle Cretella whittles down "thousands of deaths" to 11 - The Slowly Boiled Frog

Recommendation and review posted by Bethany Smith

Anabolic steroids additionally called androgenic steroids are derivatives of testosterone, significant for advancing and keeping up muscle development and creating auxiliary male sex qualities, for example, an extending voice and facial hair. They are anabolic and increment protein inside cells, particularly in skeletal muscles, Anabolic steroids utilized restoratively in ailments to animate muscle increment, set off male adolescence and treat constant squandering conditions, comprising of malignancy and AIDS.

Increment in geriatric populace drives the androgens and anabolic steroids commercial center, as more men are susceptible to hypogonadism. Also, ascend in weight issues in men propels the overall androgens and anabolic steroids market. The growing negative health status specifically within the developing countries is projected to fuel the growth of the marketplace during the forecast period. Besides, rise in government ventures for higher human services is attributed to the growth of the overall androgens and anabolic steroids market. Increment in occurrence of hypogonadism among men is anticipated to enlarge the worldwide androgens and anabolic steroids market all through the forecast span. Rise in impotence among men due to weight problems and tiredness is expected to enhance demand for androgens and anabolic steroids during forecast duration.

Request for Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/29509

Anabolic Steroids Market can be segmented on basis of compound derivatives, mode of administration, applications, Distribution channels and geography.

On basis of synthetic derivatives, Anabolic steroids market is segmented as:

On basis of Modes of administration, Anabolic steroids is segmented as:

On basis of Applications, anabolic steroids is segmented as:

On basis of Distribution channels, anabolic steroids market is segmented as:

Anabolic steroids include di-hydro-testosterone, testosterone, and other marketers. Anabolic steroids stimulate the improvement of male sex organs and male sexual characters including growth of beard and deepening of voice. Various varieties of tissues grow due to stimulation of anabolic steroids, specifically muscle and bone. Rise in red blood cells production is due to anabolic results. Androgens and anabolic steroids are used for the remedy of breast cancer in ladies, impotence, hypogonadism in men, and alternative therapy delayed puberty in adolescent boys. Anabolic steroids are also used for the treatment of numerous conditions with hormonal imbalance, weight loss, osteoporosis, and anemia. Anabolic steroids market can be segmented based on synthetic derivatives, mode of administration, application, end-user, and region. In terms of mode of administration, the market can be categorized into oral, injection, topical, skin patches and inhaler. Based on application type, anabolic steroids market can be divided into Anabolic, Androgenic and others. Based on distribution channels anabolic steroids market can be classified into hospital pharmacies, retail pharmacies and online pharmacies. The hospital pharmacies segment dominated the market owing to elevated availability of medications and hospitals being the first point of contact for treatment.

If you have any query, ask the analyst @ https://www.persistencemarketresearch.com/ask-an-expert/29509

Anabolic steroids market in North America held the biggest marketplace share due to expanded prevalence of breast cancer in women. According to many researches, breast cancers is one of the main cause of death in U.S. Europe held the second largest share in anabolic steroids market because of accelerated occurrence of hypogonadism in men and delayed puberty in adolescent boys. The Anabolic steroids market in Asia Pacific is expected to grow at a fast pace during the forecast period attributable to multiplied government initiatives to get rid of breast cancer. Anabolic steroids market in Middle East & Africa is predicted to be driven via improved occurrence of impotence, hypogonadism in men, and behind schedule puberty in adolescent boys. The market in Latin America is projected to witness robust increase at some point of the forecast length due to accelerated government tasks within the fitness care sector.

Valeant, Endo Pharmaceuticals Solutions Inc., Germiphene Corporation, Taro Pharmaceuticals, Inc., Antares Pharma, Inc, Actavis Pharma, Inc, Sandoz, Pfizer, Unimed Pharmaceuticals, Upsher-Smith and others

See original here:
Rapid Advancements in Anabolic Steroids Market to Fuel Revenues Through 2029 - Space Market Research

Recommendation and review posted by Bethany Smith

A newly designed viral vector the vehicle that delivers a gene therapyto a patients cells for use insickle cell anemia is more efficient than earlier vectors at introducing healthy copies of genes into stem cells and can be produced in greater amounts, studies in animal models show.

The study Development of a forward-orientated therapeutic lentiviral vector for hemoglobin disorders was published in the journal Nature Communications.

Hemoglobin is the protein in red blood cells that binds oxygen, allowing oxygen to be transported around the body. Mutations in the HBBgene, which encodes a component of hemoglobin, causessickle cell.

Gene therapies involve either altering the mutated gene or introducing a healthy version of that gene to the body. Still under development for sickle cell, an estimated 27 patients have undergone experimental gene therapy. One strategy involves removing hematopoietic stem cells (which function to produce blood cells) from a patients bone marrow. A healthy copy of the HBB gene is then introduced into the cells using a modified, harmless virus known as a viral vector. The cells are then transplanted back into the patient where they will produce healthy red blood cells.

Traditionally, viral vectors for sickle cell have been designed in a way known as reverse structural orientation. This means that the HBB gene is translated or read from right to left, like reading an English sentence backwards. The reverse structural orientation design ensures that a key section of the gene (known as intron 2), which is necessary for the production of high levels of the HBB gene, is retained during viral vector preparation.

However, this design makes preparing the viral vectors more difficult, and decreases the efficiency of introducing the gene into the stem cells.

Researchersat the National Institutes of Healthdesigned a new viral vector, one in which the HBB gene is forward orientated and read from left to right. Genes essential for the virus were inserted into intron 2, meaning that only vectors that retained intron 2 would be produced (a type of positive selection).

Our new vector is an important breakthrough in the field of gene therapy for sickle cell disease, John Tisdale, MD, chief of the Cellular and Molecular Therapeutic Branch at the National Heart, Lung, and Blood Institute (NHLBI) and the studys senior author, said in a press release.

Its the new kid on the block and represents a substantial improvement in our ability to produce high capacity, high efficiency vectors for treating this devastating disorder, he added.

The researchers compared the new vectors to traditional reverse-orientated vectors in mouse and monkey models. The new vectors were four to 10 times more efficient at introducing the healthy HBBgene into the stem cells, and could carry up to six times more HBB genes compared to the conventional vectors.

Furthermore, the new vectors remained incorporated into the cells of monkeys up to four years after a transplant. These vectors could also be produced in greater amounts, which may lessen the time and costs required for large-scale vector production.

The researchers hope that these characteristics will make gene therapy for sickle cell disease more effective and increase its use. The new vector design still needs to be tested in clinical trials in patients.

Our lab has been working on improving beta-globin vectors for almost a decade and finally decided to try something radically different and it worked, Tisdale said.

These findings bring us closer to a curative gene therapy approach for hemoglobin disorders, he added.

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

Total Posts: 94

Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Tcnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.

Read the original here:
New Viral Vector for Sickle Cell Gene Therapy Likely to Be More Effective, NIH Study Says - Sickle Cell Anemia News

Recommendation and review posted by Bethany Smith

PENNY Lancaster was reduced to tears as she handed five-year-old Ronnie Musselwhite the Young Hero gong at The Suns Who Cares Wins health awards last night.

Spurs fan Ronnie bravely offered to give his older sister Ebonie a bone marrow transplant last year.

Eight-year-old Ebonie had leukaemia and it was her only hope.

Mum Christine Jenkins, 40, said: Ronnies stem cells worked perfectly. They did what they were supposed to do but the leukaemia came back somewhere new.

Ebonie, of Crawley, West Sussex, nominated her younger brother before her death in June.

Rod Stewarts partner Penny chatted with Ronnie about his love of football and Spurs.

She said: To say I am humbled to be here is an understatement. Sometimes you think life has turned a corner on you, but then someone else turns up to give you some inspiration.

"The courage this little man has shown is absolutely incredible. Hes only five years old, hes lost a sister.

"He was incredibly shy to stand up in front of everyone to collect his award, but he again was so brave.

Christine said: We want Ronnie to know that what he did still worked, was still brave, even though he lost his sister.

PM Boris Johnson was also at the awards held at The Suns London HQ near The Shard and paid tribute to our NHS heroes.

He presented an award to a pair of quick-thinking hospital porters who saved the life of a seven-week-old baby boy.

Nick Evans, 48, and Ruth Lowe, 47, sprang into action after Logan Clifford stopped breathing.

His parents, Sarah and Mike were visiting a relative at the Princess Royal Hospital in Telford, Shrops, when they noticed Logans lips had turned blue.

Sarahs screams alerted Ruth, who shouted for Nick. He grabbed Logan and performed CPR as he ran half a mile down the corridor to A&E.

Nick continued CPR until the resuscitation team took over and the porters stayed by Logans parents side until they knew he was going to be OK. Sarah, 30, has called the two porters my heroes.

As he handed the pair the Ultimate Lifesaver trophy, the PM said: The NHS is revered around the world, and in no small part due to the heroes working in it every day.

He added: My experience of the NHS is like everybody else in the NHS - one of admiration and love.

"It is the most extraordinary institution in the world. If our country was an omelette then the NHS is the egg white that holds the great British cake together.

Virgin Radio DJ Chris Evans presented the Best Nurse gong to Liz Monaghan, 53. She set up the widely praised Purple Rose initiative, which aims to improve the care for patients and their loved ones in the last days of their life.

Liz, who works at the Florence Nightingale Hospice, based at the Stoke Mandeville Hospital in Aylesbury, Bucks, said: Im a little embarrassed to have won. Im a small part of a big team.

DJ Chris said: Youve got to prepare yourself for nights like this because otherwise they hit you like an express train.

Who Cares Wins Awards: The winners

BEST HEALTH CHARITY

Winner: Matt Hampson Foundation

Former English rugby union player Matt Hampson set up a charity to help others after being left paralysed in a scrum in 2005.

Other nominees: Superhero Foundation and Team Domenica

BEST NEONATAL SPECIALIST

Winner: Professor Kypros Nicolaides

Professor Nicolaides performed pioneering keyhole surgeon on Sherrie Sharps unborn son Jaxon. By extraordinary coincidence, as a young surgeon, he also operated on Sherries mother when she was in the womb.

Other nominees: Dr Vesna Pavasovic and Professor Massimo Caputo

UNSUNG HERO

Winner: Therapeutic Care Volunteers at South Tees NHS Foundation Trust

30 therapeutic care volunteers, who all have a learning or physical disability, give up their time to support patients with spinal injuries at The James Cook University Hospital in Middlesbrough. They include Ify Nwokoro.

Other nominees: Ben Slack and Rob Allen

GROUNDBREAKING PIONEER

Winner: Guys and St Thomas London Auditory Brainstem Implant (ABI) Service

Leia Armitage, eight, was born with a rare form of deafness and was never expected to speak. But she now can thanks to pioneering brain surgery and speech therapy carried out by Guys and St Thomas London Auditory Brainstem Implant (ABI) Service.

Other nominees: Dr Helen Spencer and Girish Vajramani

BEST DOCTOR

Winner: Dr Matthew Boulter

Dr Boulter served in Afghanistan, teaches wild trauma to army medics and his surgery became the first in Cornwall to be given veteran friendly accreditation.

Other nominees: Margaret France and Dr Bijay Sinha

BEST MIDWIFE

Winner: Jane Parke

Jane helped deliver the youngest surviving twin boys in Britain when they were born at 22 weeks last year. She flew 190 miles with their mum Jennie Powell to a specialist neonatal unit.

Other nominees: Charlotte Day and Nagmeh Teymourian

ULTIMATE LIFESAVER

Winner: Ruth Lowe and Nick Evans

Porters Ruth and Nick saved the life of Sarah and Mike Cliffords seven-week-old baby Logan. He stopped breathing as they walked through the main entrance of The Princess Royal Hospital in Telford to visit a sick relative.

Other nominees: Dr Mark Forrest and Mike Merrett

BEST NURSE

Winner: Liz Monaghan

Liz is the Matron of the Florence Nightingale Hospice in Aylesbury, Bucks, and came up with the idea for the widely praised Purple Rose initiative to improve the care for patients in the last days of their lives.

Other nominees: Margaret Ballard and Carlton DeCosta

MENTAL HEALTH HERO

Winner: Ben West

Ben lost his brother Sam, 15, to suicide last year and since his death, has campaigned tirelessly to raise awareness for mental health.

Other nominees: Beth Gregan and Catherine Benfield

YOUNG HERO

Winner: Ronnie Musselwhite

Ronnie offered to help his sister Ebonie by giving her a bone marrow transplant when she was diagnosed with a rare form of leukaemia. Ebonie nominated her brother for his bravery before she died in June.

Other nominees: Bella Field and Kaitlyn Wright

I only walked ten metres into the room tonight and I already nearly burst into tears three times.

TV star Christine Lampard gave the Best Neonatal Specialist award to Prof Kypros Nicolaides, 66.

He was nominated by Sherrie Sharp, 29, of Horsham, West Sussex, for saving the life of her unborn baby son and her own.

After scans revealed Jaxson had spina bifida, Sherrie was offered a termination. But she contacted Prof Nicolaides, a surgeon at Kings College Hospital, London.

He had saved her life 30 years earlier when she developed a rare blood disorder in her mums womb.

He agreed to perform ground-breaking surgery on Jaxson while he was in Sherries womb.

Prof Nicolaides said: I was delighted to be able to help. Sherrie said: He has saved so many generations of my family. Hes our guardian angel.

The Who Cares Wins Awards were set up in 2017 by The Sun to honour the nations heroic doctors, nurses, midwives, other NHS staff and volunteers.

The Duchess of York presented an award to the parents of Natasha Ednan-Laperouse, 15, who died of an allergic reaction to a sandwich from Pret.

The duchess said: Can I just say to The Sun, I think youre incredible. Every minute Im sitting there and thinking Im so lucky. The NHS, The Sun and all of you, this is what makes Britain so great.

Lorraine Kelly, who presented the awards, said: Earlier on this year my dad was very sick and we honestly thought we were going to lose him.

"It was really difficult and it was only because of the efforts of the NHS hes still here. Its fantastic.

Who Cares Wins Awards: The winners

BEST HEALTH CHARITY

Nominees: Superhero Foundation

Team Domenica

Winner: Matt Hampson Foundation

Former English rugby union player Matt Hampson set up a charity to help others after being left paralysed in a scrum in 2005.

BEST NEONATAL SPECIALIST

Nominees: Dr Vesna Pavasovic

Professor Massimo Caputo

Winner: Professor Kypros Nicolaides

Professor Nicolaides performed pioneering keyhole surgeon on Sherrie Sharps unborn son Jaxon. By extraordinary coincidence, as a young surgeon, he also operated on Sherries mother when she was in the womb.

UNSUNG HERO

Nominees: Ben Slack

Rob Allen

Winner: Therapeutic Care Volunteers at South Tees NHS Foundation Trust

30 therapeutic care volunteers, who all have a learning or physical disability, give up their time to support patients with spinal injuries at The James Cook University Hospital in Middlesbrough. They include Ify Nwokoro.

GROUNDBREAKING PIONEER

Nominees: Dr Helen Spencer

Girish Vajramani

Winner: Guys and St Thomas London Auditory Brainstem Implant (ABI) Service

Leia Armitage, eight, was born with a rare form of deafness and was never expected to speak. But she now can thanks to pioneering brain surgery and speech therapy carried out by Guys and St Thomas London Auditory Brainstem Implant (ABI) Service.

BEST DOCTOR

Nominees: Margaret France

Dr Bijay Sinha

Winner: Dr Matthew Boulter

Visit link:
Penny Lancaster is reduced to tears as she gives bone marrow donor Ronnie Musselwhite, 5, The Suns Young H - The Sun

Recommendation and review posted by Bethany Smith

Global Cell Therapy Technologies Market was valued US$ 12 billion in 2018 and is expected to reach US$ 35 billion by 2026, at CAGR of 12.14 %during forecast period.

The objective of the report is to present comprehensive assessment projections with a suitable set of assumptions and methodology. The report helps in understanding Global Cell Therapy Technologies Market dynamics, structure by identifying and analyzing the market segments and projecting the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, growth strategies, and regional presence. To understand the market dynamics and by region, the report has covered the PEST analysis by region and key economies across the globe, which are supposed to have an impact on market in forecast period. PORTERs analysis, and SVOR analysis of the market as well as detailed SWOT analysis of key players has been done to analyze their strategies. The report will to address all questions of shareholders to prioritize the efforts and investment in the near future to the emerging segment in the Global Cell Therapy Technologies Market.

REQUEST FOR FREE SAMPLE REPORT: https://www.maximizemarketresearch.com/market-report/global-cell-therapy-technologies-market/31531/#requestforsample

Global Cell Therapy Technologies Market: OverviewCell therapy is a transplantation of live human cells to replace or repair damaged tissue and/or cells. With the help of new technologies, limitless imagination, and innovative products, many different types of cells may be used as part of a therapy or treatment for different types of diseases and conditions. Celltherapy technologies plays key role in the practice of medicine such as old fashioned bone marrow transplants is replaced by Hematopoietic stem cell transplantation, capacity of cells in drug discovery. Cell therapy overlap with different therapies like, gene therapy, tissue engineering, cancer vaccines, regenerative medicine, and drug delivery. Establishment of cell banking facilities and production, storage, and characterization of cells are increasing volumetric capabilities of the cell therapy market globally. Initiation of constructive guidelines for cell therapy manufacturing and proven effectiveness of products, these are primary growth stimulants of the market.

Global Cell Therapy Technologies Market: Drivers and RestraintsThe growth of cell therapy technologies market is highly driven by, increasing demand for clinical trials on oncology-oriented cell-based therapy, demand for advanced cell therapy instruments is increasing, owing to its affordability and sustainability, government and private organization , investing more funds in cell-based research therapy for life-style diseases such as diabetes, decrease in prices of stem cell therapies are leading to increased tendency of buyers towards cell therapy, existing companies are collaborating with research institute in order to best fit into regulatory model for cell therapies.Moreover, Healthcare practitioners uses stem cells obtained from bone marrow or blood for treatment of patients with cancer, blood disorders, and immune-related disorders and Development in cell banking facilities and resultant expansion of production, storage, and characterization of cells, these factors will drive the market of cell therapy technologies during forecast period.

On the other hand, the high cost of cell-based research and some ethical issue & legally controversial, are expected to hamper market growth of Cell Therapy Technologies during the forecast period

AJune 2016, there were around 351 companies across the U.S. that were engaged in advertising unauthorized stem cell treatments at their clinics. Such clinics boosted the revenue in this market.in August 2017, the U.S. FDA announced increased enforcement of regulations and oversight of clinics involved in practicing unapproved stem cell therapies. This might hamper the revenue generation during the forecast period; nevertheless, it will allow safe and effective use of stem cell therapies.

Global Cell Therapy Technologies Market: Segmentation AnalysisOn the basis of product, the consumables segment had largest market share in 2018 and is expected to drive the cell therapy instruments market during forecast period at XX % CAGR owing to the huge demand for consumables in cell-based experiments and cancer research and increasing number of new product launches and consumables are essential for every step of cell processing. This is further expected to drive their adoption in the market. These factors will boost the market of Cell Therapy Technologies Market in upcoming years.

On the basis of process, the cell processing had largest market share in 2018 and is expected to grow at the highest CAGR during the forecast period owing to in cell processing stage,a use of cell therapy instruments and media at highest rate, mainly in culture media processing. This is a major factor will drive the market share during forecast period.

Global Cell Therapy Technologies Market: Regional AnalysisNorth America to held largest market share of the cell therapy technologies in 2018 and expected to grow at highest CAGR during forecast period owing to increasing R&D programs in the pharmaceutical and biotechnology industries. North America followed by Europe, Asia Pacific and Rest of the world (Row).

Do Inquiry Before Purchasing Report Here: https://www.maximizemarketresearch.com/market-report/global-cell-therapy-technologies-market/31531/#inquiry

Scope of Global Cell Therapy Technologies Market

Global Cell Therapy Technologies Market, by Product

Consumables Equipment Systems & SoftwareGlobal Cell Therapy Technologies Market, by Cell Type

Human Cells Animal CellsGlobal Cell Therapy Technologies Market, by Process Stages

Cell Processing Cell Preservation, Distribution, and Handling Process Monitoring and Quality ControlGlobal Cell Therapy Technologies Market, by End Users

Life Science Research Companies Research InstitutesGlobal Cell Therapy Technologies Market, by Region

North America Europe Asia Pacific Middle East & Africa South AmericaKey players operating in the Global Cell Therapy Technologies Market

Beckman Coulter, Inc. Becton Dickinson and Company GE Healthcare Lonza Merck KGaA MiltenyiBiotec STEMCELL Technologies, Inc. Terumo BCT, Inc. Thermo Fisher Scientific, Inc. Sartorius AG

MAJOR TOC OF THE REPORT

Chapter One: Cell Therapy Technologies Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Cell Therapy Technologies Market Competition, by Players

Chapter Four: Global Cell Therapy Technologies Market Size by Regions

Chapter Five: North America Cell Therapy Technologies Revenue by Countries

Chapter Six: Europe Cell Therapy Technologies Revenue by Countries

Chapter Seven: Asia-Pacific Cell Therapy Technologies Revenue by Countries

Chapter Eight: South America Cell Therapy Technologies Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Cell Therapy Technologies by Countries

Chapter Ten: Global Cell Therapy Technologies Market Segment by Type

Chapter Eleven: Global Cell Therapy Technologies Market Segment by Application

Chapter Twelve: Global Cell Therapy Technologies Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Cell Therapy Technologies Market Report at: https://www.maximizemarketresearch.com/market-report/global-cell-therapy-technologies-market/31531/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

Follow this link:
Global Cell Therapy Technologies Market Industry Analysis and Forecast (2018-2026) - Weekly Spy

Recommendation and review posted by Bethany Smith

Mathew Knowles, father to Beyonc and Solange, revealed on "Good Morning America" that he's been battling breast cancer. USA TODAY

As Breast Cancer Awareness Month begins, few people think about the men affected.

Beyoncs father, Mathew Knowles, revealed on "Good Morning America"Wednesday that he is battling breast cancer and urged other men to get tested for the disease.

The American Cancer Society estimates about 2,670 new cases of invasive male breast cancer will be diagnosed in the USAin 2019, and about 500 men will die from the disease.

Mary Smania, assistant professor at Michigan State University's College of Nursing, said breast cancer in men is extremely rare less than 1% butcarries dangerous consequences.

Should you get a 3D mammogram?: What you should know about how the screening detects breast cancer

The American Cancer Society lists signs and symptoms of male breast cancer:

Sometimes breast cancer can spread and cause swellingunder the arm or around the collar bone, even before the original tumor in the breast isn't big enough to be felt, according to the organization.

"It's a little bit easier to detect," Smania said. "Typically because they don't have the amount of breast tissue that women have."

Routine breast screenings don't exist for men likethey do for women, Smania said, so it's important to see a health care professional with any concerns.

Lyndsay Rhodes, associate professor of biological sciences at Florida Gulf Coast University, said knowing the symptoms is a great first step to early detection.

"Being aware of symptoms can save lives," Rhodes said. "Early detection is key."

Battling cancer for the 3rd time: Olivia Newton-John 'had to learn to walk again' amid stage 4 breast cancer battle

The ACS noted that cells in nearly any part of the body can be susceptible to cancer and can spread to other areas of the body.

The organization's website says cancer can start at different parts of the breast, such in the ducts that carry milkto the nipple or the glands that make breastmilk. Although men's breasts don't produce milk like women's, their bodies havethese ducts and glands.

Smania said the most common form of breast cancer in men is the invasive ductal carcinoma, which the ACS said starts in the milk duct, breaks through the wall of the duct,then grows into the fatty tissue of the breast where it has the potential to spread.

An athlete's battle: Syracuse basketball star perseveres in breast cancer fight

When a man is diagnosed with breast cancer, Smania said, doctors usually do genetic testing as well to determine if he carries BRCA1 or BRCA2 mutations, also known by the National Breast Cancer Foundation as the "Breast Cancer Gene."

These mutations are genetic and can be passed down to children, which would significantly increase the chances of a daughter having breast cancer, Smania said.

The National Breast Cancer Foundation said 55%-65% of women with the BRCA1 mutation and about 45%with the BRCA2 mutation will develop breast cancer by the age of 70.

"Education in this matter is critical," Rhodes said."Men are statistically less likely to have a primary care physician, go to yearly examsor conduct self breast exams."

'Im lucky to be alive': '90210' star Shannen Doherty gets candid on breast cancer battle

Autoplay

Show Thumbnails

Show Captions

Read or Share this story: https://www.usatoday.com/story/news/health/2019/10/02/beyonces-dad-has-male-breast-cancer-what-symptoms/3839922002/

Continue reading here:
Male breast cancer awareness: Why Beyonce's father, Mathew Knowles, urges men to get tested - USA TODAY

Recommendation and review posted by Bethany Smith

The Project Management Institute (PMI) announced its 2019 Most Influential Projects list. This ranking cites the most impactful projects from the past 50 years, with the World Wide Web hitting the #1 spot followed by Apollo 11, and including such projects as Walt Disney World, Harry Potter, World of Warcraft and the Sydney Opera House.

The list is also broken out into subcategories, including biotech. Heres a look at the biotech list.

#1. Human Genome Project. This ranked #5 on their overall list, and it indeed is one of the most influential life science projects, changing and informing healthcare and biology as we know it. One simple example is the overturning of the central dogmawhich up until the completion of the project, was that one gene coded for one protein. Since there were about a hundred thousand known proteins, scientists had concluded there must be the same number of genes. However, it turned out that in human beings, there were about 30,000 genes and they are read in a variety of unexpected ways to code for those 100,000-plus genes.

The project launched officially in 1990 and drew on laboratories and institutions from around the world, including from the U.S. Department of Energy, the U.S. National Institutes of Health (NIH), the UKs Sanger Centre (later the Wellcome Sanger Institute) and 17 university and laboratory sequencing centers.

#2. First IVF Baby. This year was the 41st birthday of the first so-called test tube baby, Louise Brown, who was born on July 25 in 1978. The process is in vitro fertilization. Now commonplace, the procedure was incredibly controversial at the time. Louises mother, Lesley Brown, hadnt been able to conceive naturally as the result of blocked Fallopian tubes. She had been trying to conceive for nine years when she signed up for IVF, which was then an experimental procedure. She was one of 282 women who tried the procedure. At that time, doctors attempted 457 egg collections, but only 167 cycles led to fertilization. From 12 embryos that were successfully implanted, five became pregnant. Louise was the only live birth. Since then, about six million children have been born via IVF.

#3. CRISPR. CRISPR stands for clustered regularly interspaced short palindromic repeats, which is otherwise a fast and easy way to edit DNA. CRISPR-Cas9 allows researchers to easily identify specific gene sequences, clip them out and replace them. It has been cited as one of the most important and recent discoveries that could lead to new therapies and treatments for numerous diseases. In November 2018, it hit the spotlight with a major controversy when He Jiankui, a researcher in Shenzhen, China, announced he had utilized CRISPR-Cas9 to alter the DNA of embryos for seven couples. He used CRISPR to disable a gene called CCR5. CCR5 codes for a protein that allows HIV to enter a cell. In theory, the children born from the procedure should be resistant to HIV. The fathers all had HIV infections that were strongly suppressed by standard HIV drugs. The announcement was met by wide international condemnation, the eventual moratorium on using CRISPR germline editing, and He Jiankui being investigated by the Chinese government.

#4. Genetic Fingerprinting. Perhaps more accurately described now as forensic DNA analysis, genetic fingerprinting is a way of using DNA samples in criminal investigations to identify perpetrators (and victims). It was first introduced in 1984 by a researcher at the University of Leicester in the UK, Alec Jeffreys. The first practical application was in a 1985 immigration case, which was followed by a paternity case. The first criminal forensic case was applied to the case of two girls who were raped and murdered in the Enerby area of Leicestershire. There was a confession for one of the murders. They used the forensic test in an attempt to prove he committed the second, but unexpectedly, the test proved he was innocent of both murders. The police force then conducted blood draws and genetic profiles on the entire male population of that area. Again, no matches were found until a man named Colin Pitchfork bragged about how he had convinced a friend to provide the sample. He was a match for both rape and murders.

#5. 23andMe. 23andMe was founded in 2006 by Linda Avey, Paul Cusenza and Anne Wojcicki. It began by marketing a saliva-based direct-to-consumer personal genome test. However, the U.S. Food and Drug Administration (FDA) forced the company to pull it from the market because it was advertised as a medical device, which required FDA approval, which 23and Me did not have. The kits are still available, but health-related reports that came with it were no longer included. The company has since inked deals with major pharma companies, such as Pfizer, to use its genomics data in disease and drug research and development. In March 2018, the FDA approved 23andMes BRCA1 and BRCA2 genetics tests as the first-ever FDA approval for a DTC consumer genetic test for cancer risk, in this case, breast, ovarian and prostate cancer.

#6. Dolly. Although it seems like a distant memory, Dolly was the first mammal to be cloned from the cell of an adult. This was in 1996. Dolly was a sheep. Dolly was cloned by researchers at The Roslin Institute who were working to develop a better way to produce genetically modified livestock. The research was led by Ian Wilmut. Dolly was cloned from a cell acquired from the mammary gland of a six-year-old Finn Dorset sheep and an egg from a Scottish Blackface sheep. She was born to her Scottish Blackface surrogate mother on July 5, 1996. Oddly enough, because her DNA was taken from a mammary gland cell, she was named after country singer Dolly Parton.

#7. Engineered Organ. In 1999, Anthony Atala and his research group grew bladders in the laboratory and successfully implanted them into patients. Atala is the W.H. Boyce professor and director of the Wake Forest Institute for Regenerative Medicine and chair of the Department of Urology. Atala and his team took a bladder biopsy from each patient, isolated muscle and specialized urothelial cells, and grew them in the laboratory. They then implanted them onto a bladder-shaped scaffold where they grew for seven to eight weeks. They then attached the engineered bladder to the patients own bladder and followed the progress for up to five years. The bladder function improved without any of the side effects generally linked to implanting bowel tissue. The research paved the way for bioprinting of organs.

#8. Beyond Meat Burger. Beyond Meat developed a plant-based burger that mimics the taste of hamburger. The first plant-based burger was sold commercially in 2016. As of June 2019, the company had a $10 billion market cap and led the way for a variety of other companies to produce what are essentially genetically-modified vegetables that use a variety of ingredients, such as heme, to mimic the taste of beef. Although nutritionally about the same as beeftypically they have caloric levels similar to beef, with higher carbohydrate and salt levels with generally lower fat levelsthe primary benefit is taking animals out of the protein production chain, which may have benefits for decreasing climate change.

#9. Golden Rice. The Golden Rice Project notes that Golden Rice is the first purposefully created biofortified food. The technology behind Golden Rice was donated in 2000 by its inventors, Ingo Potrykus and Peter Beyer. Golden Rice is a not-for-profit project that involved genetically modified rice to address vitamin A deficiency, which affects about 250 million children around the world. Potrykus was then a professor at the Swiss Federal Institute of Technology in Zurich, teamed with Peter Beyer from the University of Freiberg in Germany.

#10. Kymriah. Perhaps it would have been more appropriate to identify Immunotherapy or Immuno-Oncology as one of the projects, rather than Novartis Kymriah (tisagenlecleucel), even though Kymriah was the first CAR-T immuno-oncology therapy approved. The entire field of immuno-oncology has exploded in the last decade, revolutionizing cancer treatments and is beginning to make progress in other indications as well. The other approved CAR-T product is Gilead Sciences Yescarta (axicabtagene ciloleucel). They are approved for slightly different, but sometimes overlapping patient populations. Kymria is approved for pediatric and young adult acute lymphocytic leukemia (ALL) and for recurrently relapsing (r/r) aggressive lymphomas. Yescarta is approved for similar aggressive lymphomas.

CAR-T is a type of therapy where blood samples are taken from a patient, the patients white blood cells are processed to be supercharged to attack their cancer cells, then reinfused into the patient. It is a type of living therapy where the patients immune system is programmed to better attack the cancer.

See the original post here:
50 Years of Life Sciences Innovation: PMI's Top 10 Impactful Biotech Projects - BioSpace

Recommendation and review posted by Bethany Smith

As Breast Cancer Awareness Month kicks off this October, a UNLV public health professor is reminding people that men are also at risk.

Statistics show that about 1 in 8 U.S. women will develop invasive breast cancer over the course of her lifetime, leading to it be seen primarily as a womans disease.

But that view unintentionally creates a health disparity for men, who with a lifetime risk of developing breast cancer sitting at about 1 in 883 often face barriers to diagnosis and treatment due to a lack of awareness among the general public, policymakers, and health care professionals, says Marya Shegog, director of health programs at The Lincy Institute at UNLV.

We recently sat down with Shegog to talk about her new collaboration with University of Alabama professor Raheem Paxton and the Male Breast Cancer Coalition that delved into the survivor stories of nearly 200 men who faced misdiagnoses, reduced access to care, and stigma to learn more about this phenomenon and what can be done about it.

Men account for less than 1% of all breast cancer diagnoses in the United States which consequently leads many in society to view it solely as a "womans disease.

When men are diagnosed, in a very odd way their masculinity is questioned or challenged. Often the response is, Well, youre a man. Or are you a girl now? When talking about stigma, one gentleman shared the story of how he was leading a breast cancer fundraiser yet was still afraid to come out and say he had it too.

Equally troubling, this lack of awareness creates an inability for doctors to diagnose men because when they see symptoms they dont immediately think of breast cancer as being a potential cause.

The medical community has only recently began to hypothesize that hereditary breast cancer might extend to men too, and that men can not only carry the gene but it could express itself. In one of the survivor stories we encountered, it turned out that a man who was finally diagnosed after a lengthy series of misdiagnoses looked at his family tree and realized his mother plus 12 other female relatives had been diagnosed with breast cancer. As a result, he encouraged his younger male relatives to seek genetic testing and they found out that they carried the gene as well.

Theres a lack of consideration when it comes to men and the possibility of having breast cancer.

One man first found the lump while undergoing a pre-authorization physical to play high school football. The doctor said, Thats just you becoming a man. Itll go away. So, the man ignored the lump throughout college and it wasnt until he got his first job with health insurance that he went back to a doctor and received a breast cancer diagnosis. Hed had the lump for six years, cutting survival rates and options for treatment. Luckily, it had not metastasized.

The majority of the policies and qualifiers for breast cancer treatment are female-focused, so even when a man is diagnosed early on his pathway to treatment and recovery can be confounded. One example is a survivor in South Carolina who couldnt qualify treatment because Medicaid policy requires that patients have a pap smear prior to obtaining breast cancer treatment.

Insurance is a part of the business of healthcare, so they create a set of guidelines that just checks boxes whether theres human interaction or not. For example, an insurance salesperson who was surprised that his own policy was retroactively canceled. Yet another person who called to get approval for a mastectomy was told that the insurance company doesnt approve of sex-reassignment surgery.

Some policies require mammograms, which compresses the breast between two plates. Now, imagine that for a mans breast, which is so much smaller than most womens. One man recounted how bruised he was from the mammogram. And to make matters worse, the post-recovery kit included a pink ice pack with instructions to tuck it into your bra. The person performing the procedure just handed it to him without considering finding a way for the male patient to effectively adhere it to the skin, perhaps with compression tape or an elastic bandage.

Sometimes in our vigor to address a health disparity, we can create another one. If our clinicians arent prepared or dont have the skills to readily identify breast cancer in patients, it means that men are going without getting checked this creates a complication in itself and cuts men out of the picture.

The story surrounding breast cancer has been solely women-focused and therefore omits the opportunity for men to share the story. And that means theyre omitted from the narrative and from treatment.

With gender roles, a man having breast cancer has nothing to do with his level of masculinity or sexuality. The fact that our society makes that statement is problematic in the least.

Years ago, women were dying of breast cancer in large numbers simply because doctors hadnt figured out the science behind it. My suspicion is there are now more men dying from cancer that may have started in their breast than what we know and its simply because theyre not being tested until the cancer has metastasized.

Men and women and especially parents everyone needs to know that breast cancer does not discriminate for just women. Policies around breast cancer need to be considered without gender bias. They need to be written in a way that anybody whos diagnosed can get treatment in an expeditious manner.

I think health care professionals need to change their focus. They need to be taught and be aware that its genetic. So much of our preventative measures include gene mapping. Men who may be at risk need to know theyre at risk and they need to be tested so they can act accordingly.

When women get a physical, theyre asked to fill out a form that includes questions about family history surrounding breast cancer. The same informational posters hanging in OBGYN offices need to be hanging in general practitioners offices so that men can be aware too. Those family history questions about breast cancer should be universal.

Everyone men and women alike should know their risk for getting breast cancer. And if they are at high risk, make sure theyre proactive with screenings annually or genetic testing. Really, its about knowing your risk and what you can do to prevent it.

Here is the original post:
The Blue in the Pink: Busting Myths About Male Breast Cancer - UNLV NewsCenter

Recommendation and review posted by Bethany Smith

But until recently, villagers did not know how malaria was transmitted. So when scientists came into the village in 2012 saying they wanted to fight the disease, many were thrilled.

At first, we didn't even know it was only the female mosquitoes who could spread malaria. They gave us information, they gave us advice to sleep under mosquito nets, Sanou said.

In the years since, researchers have conducted countless meetings explaining what malaria is, how it is transmitted, and what genetic modification is. Linguists had to translate such concepts as gene into the local Dioula language, which had no precise word for it. It took years to create tools for consent, with no precedents in Africa.

Yet several villagers anonymously told the Telegraph they had not been made aware of any risks associated with the experiment. They didnt tell us about the risks, only the advantages, a farmer said while tending to his corn.

Environmentalists warn that, in a village which depends on agriculture to survive, removing just one species of mosquitoes could disrupt the whole ecosystem in unforeseeable ways.

Read the original:
'We don't want to be guinea pigs': how one African community is fighting genetically modified mosquitoes - Telegraph.co.uk

Recommendation and review posted by Bethany Smith

HER BUSINESS: Sprays and potions that turn lifes stinks (human and cat poo, sweat-stanky shoes) into fresh, happy scents. And the latest addition: home cleaning products.VERY FIRST JOB: Burger King, but I didnt get to work the window, because I wasnt cute enough [in the words of her twenty-year-old male manager.... Whatever!].AS A KID, WHAT I WANTED TO BE WHEN I GREW UP: Fashion designer, but I didnt even know that was a job.A WEIRD THING YOULL FIND ON (OR IN) MY DESK: Incense and palo santo sticks (removes negative energy) and tarot cards or runes.HIGH SCHOOL GPA: Cminus at best (total grading on a curve).MY BEDTIME: Nine-thirty p.m. (I wake up at five-thirty a.m.)ON MY BUCKET LIST: Visiting Bhutan.A GUILTY PLEASURE: Mexican food, which I rarely eat.FAVORITE CANDY: Salted caramel.FAVORITE CHILDHOOD BOOK: Nancy Drew mysteries.AN EXPRESSION I USE A LOT THAT PEOPLE KNOW ME FOR: Anything is possiblefind a way!HOW OFTEN I CHECK MY BANK STATEMENT: Um, never. I havent balanced my checkbook since I was nineteen years old.A TOOL I ALWAYS WANT TO HAVE IN MY HOUSE: A thirty-foot-long duster. I have a cobweb now thats in one of the peaks of my house and its driving me crazy. If you have a duster, please send it over.ADVICE ID GIVE TO MY THIRTEEN-YEAR-OLD SELF: Nothing is ever as bad as it seems right now; it will all change. It always does.

The rest is here:
Read Girls Who Run The World Book Excerpt: Poo-Pourri - Refinery29

Recommendation and review posted by Bethany Smith

Dylan Stoll |Health Editor

Featured Image:Mosquitos are responsible for over 750,000 deaths per year. | Pixabay

When the movie Jaws was first released in 1975, it struck a very specific and poignant fear of sharks in the people who watched it. As most from that time period can attest to, everybody was afraid to go in the water after seeing the box-office hit for fear of meeting first-hand the gnashing and thrashing, bone-crushing and flesh-tearing teeth of the great white shark. Today, that same fear persists. The shark has forever been ingrained in our minds as a terror of the open sea, as one of our greatest foes with a penchant for human flesh, but is that terror misplaced?

What we should really fear isnt a 1,000-kilogram bundle of muscle and teeth, but a much smaller, and surprisingly much less manageable, five-milligram creature: the mosquito.

Everybody who is reading this has more than likely had their blood rudely and obnoxiously stolen by one of these terrible little monsters. We all hate them, and we all know why. Theyre annoying; they make that high pitched sound when they get near you, but most importantly; their bite leaves you with a relentlessly itchy bump that torments even the toughest of us.

But is that why you should fear the mosquito? Not exactly. It isnt the bite specifically that should scare you, but rather, what the bite may contain.

Mosquitos carry some of the most dangerous diseases known to mankind. These include: malaria, dengue, West Nile virus, chikungunya, yellow fever, filariasis, tularemia, dirofilariasis, Japanese encephalitis, Saint Louis encephalitis, Western equine encephalitis, Eastern equine encephalitis, Venezuelan equine encephalitis, Ross River fever, Barmah Forest fever, La Crosse encephalitis, and Zika fever, as well as the recently discovered Keystone virus and Rift Valley fever.

As a result, they are responsible for over 750,000 human deaths per year, a significant amount more than the measly six deaths per year attributed to those dastardly vicious sharks.

And you may think that these diseases are contained within other countries, but youve thought wrong. Western, Eastern, and St. Louis Equine Encephalitis, as well as West Nile viruses have all been found in Canadian mosquitos, with West Nile being the most prevalent.

Although the mosquito is a difficult creature to manage, there are measures that have been put in place to keep the populations under control. In the spirit of bringing things closer to home, since the beginning of June, York has been conducting a larvicide program under the authority of the local medical officer of health that will continue until the end of October. Methoprene pellets have been placed into all university catch basins, and Bacillus thuringiensis var israelensis, another type of larvicide, has been applied in granular form to specific bodies of surface water, which were chosen based on their mosquito larval content.

As for large-scale control in other countries, some interesting ideas have come to the table and have even been implemented.

One such idea is the genetic modification of non-biting male mosquitoes. The plan was to modify their DNA in such a way as to pass on a gene that would kill their offspring before sexual maturity. The ambitious venture was completed by a company known as Oxitec, which conducted a large field trial in Brazil, specifically in the city of Jacobina. They released 450,000 GM mosquitoes per week from 2013 to 2015 and they reported a 90 per cent reduced overall population.

Another method is sterilization. Dr. Andrew Donini, a professor at York who studies mosquitoes, explained the process further: The sterile males compete with regular wild males for females with the idea that females will be inseminated with sterile sperm. The eggs these females lay are unfertilized because the sperm is no good, therefore they will never produce any hatchlings/larvae. Ive read that this has been effective over the short term but one would have to keep releasing lots of sterile males to lower populations levels.

The aforementioned methods are most likely the least invasive in terms of the environment and surrounding speciesspecies that include us. There are, however, other population controllers that are much more invasive and are still in use today.

To this day some governments still spray with pesticides, clarified Donini. A good recent example is the mysterious sickness that US and Canadian diplomats experienced while working in Cuba. It turns out a study has linked that to pesticide fumigation for mosquitoes. The diplomats were exposed to levels of the pesticide that ultimately gave them a neurological illness.

As for the individual who still wishes to enjoy the outdoors without a PhD in genetics or a tank full of toxic pesticides, Donini advises that you do everything the government health agencies recommend: Dont get bit. Wear long sleeves, long pants, use DEET, and prevent stagnant water around your house.

Read the rest here:
Solving the mosquito problem - Excalibur Online

Recommendation and review posted by Bethany Smith

DNA found on two cigarette butts was the evidence King County sheriffs detectives said they needed to make an arrest in the homicide of Sarah Yarborough, a 16-year-old drill-team member who was found strangled on the campus of Federal Way High School nearly three decades ago.

Patrick Leon Nicholas was charged Thursday with first-degree murder with sexual motivation, according to King County prosecutors. Nicholas is accused of killing Yarborough while attempting to commit second-degree rape, the charges say.

Yarborough was strangled with her nylons on Dec. 14, 1991, and male DNA was found on several items of her clothing near her body, charging papers say. Nicholas, a 55-year-old Covington man, was 27 at the time of her death and lived six miles from the high school, according to the charges.

In the 28 years since Yarboroughs slaying, sheriffs detectives have submitted male DNA found at the crime scene for analysis numerous times. But there was never a match.

Then last week, Dr. Colleen Fitzpatrick, a forensic genealogist based in Fountain Valley, California, who has worked before on the Yarborough case, contacted Detective Kathleen Decker of the sheriffs Major Crimes Unit saying there was a promising lead on a person of interest, the charges say. Fitzpatrick and two other genealogists identified Nicholas and his brother through a family tree analysis based on the DNA from the Federal Way crime scene and provided Decker with the brothers names.

Both brothers have blond hair and blue eyes, matching composite drawings sheriffs detectives releasedin February 2018after investigators determined Yarboroughs killer was of Northern European descent and most likely had blue or green eyes based on genetic markers in the previously unknown DNA.

Decker determined Nicholas older brother a Level 2 sex offender who had been convicted of first-degree rape could not be Yarboroughs killer because his DNA was entered into the Combined DNA Index System (CODIS) years ago, and regular comparisons to DNA from the Yarborough crime scene never produced a hit, the charges say.

Patrick Nicholas has never submitted a DNA sample for entry into CODIS despite having a criminal record, the charges say. He was convicted in 1983 of attempted first-degree rape in Benton County and was released from prison in 1987. He was also charged in 1994 with first-degree child molestation but later pleaded guilty to fourth-degree assault, court records show.

After identifying Nicholas as a suspect in Yarboroughs death, detectives began watching him. On Sunday, a detective saw Nicholas smoking a cigarette outside a Kent dry-cleaning business and retrieved the butt from the ground, charging papers say. A short time later, Nicholas walked out of the business, smoked a second cigarette and unknowingly dropped a napkin on the ground, and both items were collected by the same detective, according to the charges.

On Monday, Decker took the items to the State Patrol Crime Lab for DNA testing and on Wednesday, a scientisttold Decker DNA found on the cigarette butts matched DNA from the Yarborough crime scene, according to the charges.

Countless hours have been spent by law enforcement attempting to solve this horrific crime that impacted our community in a way that few people have forgotten. Patrick Leon Nicholas has lived for the last several years in a dilapidated building on a large piece of property with few community ties, Senior Deputy Prosecutor Erin Ehlert wrote in charging papers. If he does not remain in custody, he has every reason to attempt to flee and avoid prosecution as he has done for the last 27 years. His crime was one of opportunity and extreme violence and he will always be considered a danger to our community.

Nicholas DNA will be entered into CODIS and compared to DNA from other unsolved cases, Ehlert wrote.

He was arrested at a Kent sports bar on Wednesday and was booked into the King County Jail, court and jail records show. Prosecutors have requested that his bail be set at $5 million.

Laura Yarborough, Sarahs mother, attended a Thursday news conference at the King County Sheriffs Office in downtown Seattle and thanked all of the detectives who have worked on her daughters case for their dogged determination.

Theyve been so professional and kind to our family. They never gave up, even when I gave up, Laura Yarborough said.

She was surprised when she got the call Wednesday night with news that an arrest had been made in connection with her daughters homicide.

I think for me, Im still a little numb. Im sure other feelings will follow, Yarborough said.

She said her daughter loved life, people and traveling. Sarah was an excellent student, always had a book at hand, and was excited about going off to college.

Sarahs friends, Yarborough said, have remained in touch with the family over the years and have maintained a Facebook page seeking justice for Sarah.

Her friends were very impacted by this. They were young and it was scary, she said.

According to charging papers:

On a cold Saturday morning in December 1991, Yarborough drove to Federal Way High School and parked in the back lot. She and other members of her drill team were to board a bus for an event at Juanita High School in Kirkland.

She arrived early a witness saw her pull in around 8:10 a.m., though the bus wasnt to depart until 9. At 8:20 a.m., another witness noticed her car engine was warm, despite the frigid temperatures.

A man jogging near the tennis courts at the high school looked over and saw a girl lying motionless on the ground, a man kneeling beside her and touching the girls breasts and thighs. The jogger thought they were a couple making out so jogged on but later provided a suspect description to police.

Then around 9:15 a.m., two 12-year-old boys were cutting through the campus on their way to the store when a man stepped out of the bushes. Both boys got a good look at him before he walked away. The boys saw Yarboroughs body and ran home and told their parents.

One parent called 911 and another walked back with the boys to the crime scene.

Yarboroughs body was found maybe 100 yards from her car, and there was no reason for her to have walked in that direction, which means she was either lured or dragged to her death, police believe.

Over the years, investigators received more than 4,000 tips about the case. After Nicholas was identified through his DNA, his name was run through the tip database but no one had ever mentioned him, the charges say.

Though charging papers dont detail how Fitzpatrick and her fellow genealogists identified Nicholas, in the past year, law enforcement has identified suspects through the DNA of relatives, who used sites such as Ancestry.com or 23andMe to generate their own DNA profiles then uploaded them to GEDmatch, a public genetic-genealogy website.

Genetic genealogy, which utilizes DNA testing and traditional genealogical methods to establish familial relationships, led to the arrest last year of Joseph James DeAngelo, the alleged serial rapist and killer known as the Golden State Killer in California. Closer to home, genetic genealogy led to the arrest of Earl Talbot II of SeaTac in the November 1987 slaying of Tanya Van Cuylenborg, 18, and 20-year-old Jay Cook, a young Canadian couple. Talbot was convicted of murder in Snohomish County Superior Court and was sentenced to two life terms in July.

See the original post here:
Arrest made in death of Federal Way teen nearly 30 years after her body was found - Seattle Times

Recommendation and review posted by Bethany Smith

DUBLIN, Oct. 7, 2019 /PRNewswire/ -- The "Novel Cell Sorting and Separation Market: Focus on Acoustophoresis, Buoyancy, Dielectrophoresis, Magnetophoretics, Microfluidics, Optoelectronics, Traceless Affinity and Other Technologies, 2019-2030" report has been added to ResearchAndMarkets.com's offering.

The Novel Cell Sorting and Separation Market: Focus on Acoustophoresis, Buoyancy, Dielectrophoresis, Magnetophoretics, Microfluidics, Optoelectronics, Traceless Affinity, and Other Technologies, 2019-2030' report features an extensive study of the current landscape and future outlook of the growing market for novel cell sorting and separation technologies (beyond conventional methods). The study presents detailed analyses of cell sorters, cell isolation kits, and affiliated consumables and reagents, that are based on the aforementioned technologies.

Advances in the fields of cell biology and regenerative medicine have led to the development of various cell-based therapies, which, developers claim, possess the potential to treat a variety of clinical conditions. In 2018, it was reported that there were more than 1,000 clinical trials of such therapies, being conducted across the globe by over 900 industry players.

Moreover, the total investment in the aforementioned clinical research efforts was estimated to be around USD 13 billion. Given the recent breakthroughs in clinical testing and the discovery of a variety of diagnostic biomarkers, the isolation of one or multiple cell types from a heterogenous population has not only become simpler but also an integral part of modern clinical R&D. The applications of cell separation technologies are vast, starting from basic research to biological therapy development and manufacturing.

However, conventional cell sorting techniques, including adherence-based sorting, membrane filtration-based sorting, and fluorescence- and magnetic-based sorting, are limited by exorbitant operational costs, time-consuming procedures, and the need for complex biochemical labels. As a result, the use of such techniques has, so far, been restricted in the more niche and emerging application areas.

Amongst other elements, the report features:

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/ss4o5a

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/novel-cell-sorting-and-separation-markets-2030-300932857.html

SOURCE Research and Markets

Go here to read the rest:
Novel Cell Sorting and Separation Markets, 2030 - P&T Community

Recommendation and review posted by Bethany Smith

The cruise director is the ship's liver because almost everything you can think of filters through them at some point.

Actor Willie Aames

October is Liver Awareness Month, the month chosen by the American Liver Foundation to raise public awareness of the importance of liver health.

As a diabetic, I see the importance, even though I'm not really sure what the old workhorse does.

Diabetes Education Online, the website of the Diabetes Teaching Center at the University of California, San Francisco states that the liver acts as the body's glucose (or fuel) reservoir and helps keep circulating blood sugar levels and other body fuels steady and constant. It stores and manufactures glucose, depending on the body's need.

The need to store or release glucose is primarily signaled by the hormones insulin and glucagon.

During a meal, the liver will store sugar or glucose as glycogen for a later time when your body needs it. When you are not eating, especially overnight or between meals, the body has to make its own sugar. The liver supplies sugar or glucose by turning glycogen into glucose in a process called glycogenolysis.

The liver can also manufacture the needed glucose by harvesting amino acids, waste products and fat byproducts. That process is gluconeogensis.

The liver also makes another fuel, ketones, when sugar is in short supply. When glycogen storage is running low, the body starts to conserve sugar supplies for organs that always require sugar. They include the brain, red blood cells and parts of the kidney. That process is called ketogenesis.

Ketones are burned as fuel by muscles and other body organs, and the sugar is saved for the organs that need it.

When you have diabetes, these bodily processes can be thrown off balance. Everything affects everything.

More and more these days I see the term fatty liver disease, but there is also nonalcoholic fatty liver disease. According to the website of the Mayo Clinic (mayoclinic.org), NAFLD is an umbrella term for a range of liver conditions affecting people who drink little to no alcohol. The main characteristic is too much fat stored in liver cells.

They say it is increasingly common around the world, especially in Western nations. In the United States, it is the most common form of chronic liver disease, affecting about one-quarter of the population.

Some people with nonalcoholic fatty liver disease can develop nonalcoholic steatohepatitis, an aggressive form of fatty liver disease marked by liver inflammation. It can progress to advanced scarring (cirrhosis) and liver failure. The damage is similar to the damage caused by heavy alcohol use.

There are usually no real signs or symptoms, but when any do appear, they can include fatigue, and pain or discomfort in the upper right abdomen.

Possible signs of this steatohepatitis include abdominal swelling, enlarged blood vessels just beneath the skin's surface, an enlarged spleen, red palms and yellowing of the skin and eyes.

There seems to be limited understanding of why some people accumulate fat in the liver and others do not. And there is also limited understanding of why some fatty livers develop inflammation that progresses to cirrhosis. But both conditions are linked to the following:

Overweight or obesity.

Insulin resistance, in which cells don't take up sugar in response to the hormone insulin.

High blood sugar (hyperglycemia), indicating prediabetes or Type 2 diabetes.

High levels of fats, particularly trigylcerides, in the blood.

A wide range of diseases and conditions can increase the risk too. They include high cholesterol, polycystic ovary syndrome, sleep apnea, underactive thyroid (hypothyroidism) and underactive pituitary gland (hypopituitarism).

Those at risk include older people, Type 2 diabetics and people with body fat concentrated in the abdomen.

The condition is a bit scary. Have a frank talk with your doctor if any of this seems familiar to you.

Email me at:

rboggs@arkansasonline.com

Style on 10/07/2019

Originally posted here:
PRACTICALLY ACTIVE: Love your liver and it will love you back - Arkansas Democrat-Gazette

Recommendation and review posted by Bethany Smith